-
Mashup Score: 4Urinary Neuroendocrine Neoplasms Treated in the “Modern Era”: A Multicenter Retrospective Review - 2 year(s) ago
: Primary urinary neuroendocrine neoplasms (U-NENs) are extremely rare thus optimal treatment is unknown. Grading and treatment are typically extrapolated from other primary sites. Since 2010, the clinical landscape for NENs has changed substantially. We performed a retrospective review of U-NENs to assess treatment patterns and oncologic outcomes of patients treated in the recent era of NEN…
Source: Clinical Genitourinary CancerCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A Systematic Review and Meta-Analysis - 2 year(s) ago
Renal cell carcinoma (RCC) is the third most common urological malignancy. Worldwide, RCC account as 16th tumor in incidence and mortality with 431,288 and 179,386 new cases and new deaths, respectively, with his incidence rising in the last years1, 2. Most patients are diagnosed with localized and regional disease, with only 15 to 25% of the patients diagnosed as metastatic disease2, 3….
Source: Clinical Genitourinary CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Great review, congrats. Our contribution about this intriguing data https://t.co/XJJDlr2IVC @fsabino_onco @fmassari79 @drenriquegrande https://t.co/N3oCS9RZNe
-
-
Mashup Score: 1The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A Systematic Review and Meta-Analysis - 2 year(s) ago
Renal cell carcinoma (RCC) is the third most common urological malignancy. Worldwide, RCC account as 16th tumor in incidence and mortality with 431,288 and 179,386 new cases and new deaths, respectively, with his incidence rising in the last years1, 2. Most patients are diagnosed with localized and regional disease, with only 15 to 25% of the patients diagnosed as metastatic disease2, 3….
Source: Clinical Genitourinary CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Outstanding talk by @DrRanaMcKay about adjuvant ICI in #RCC during our tumor board at @hosp_einstein. A controversial therapy based on the last studies, that we discussed in our recently published metaanalysis https://t.co/XJJDlr3gLa @fsabino_onco @fmassari79 @drenriquegrande https://t.co/3pImJisgmw
-
-
Mashup Score: 0
Testicular cancer is a rare malignancy affecting 1 in 1000 men internationally1. Importantly, men who are diagnosed with testicular cancer are typically young adults with a median age at diagnosis of 33 years old2. The vast majority of testicular cancers are germ cell tumors (GCT) which are broadly divided into seminoma and non-seminoma GCTs based on the histology of the tumor. Testicular cancer…
Source: Clinical Genitourinary CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
The importance of repeat imaging prior to treatment decision-making in testicular cancer. A very important issue in Testis tumor management @GTumors @SpiessPhilippe @RHamiltonUrol https://t.co/nYEMzILgXO
-
-
Mashup Score: 1Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma - 2 year(s) ago
Micro-AbstractIn this retrospective multicenter study (9 sites), including 298 patients with advanced RCC, we investigated the safety of cabozantinib with different anticoagulants. DOACs appear safe for VTE treatment for patients with RCC on cabozantinib as we did not observe any difference in major bleeding events between the no anticoagulant, LMWH, and DOAC groups. Optimized anticoagulation…
Source: Clinical Genitourinary CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @nataliagandur: 💫Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma👇📖 https://t.co/oF3paVbPIR @DrCh…
-
-
Mashup Score: 0
Muscle-invasive urothelial carcinoma (MIUC) represents 30% of newly diagnosed cases, and for these patients, systemic neoadjuvant cisplatin-based chemotherapy (NAC) prior to radical cystectomy and pelvic lymph node dissection is the standard of care by major international guidelines.1,2 However, there is real-world evidence showing that around 10% to 40% of patients do not receive NAC due to…
Source: Clinical Genitourinary CancerCategories: Latest Headlines, Oncologists2Tweet-
A Systematic Review and Meta-Analysis of the Role of Immune Checkpoint Inhibitors (ICI) as Adjuvant Treatment for Localized High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC) https://t.co/Jd7gLfeMnb
-
-
Mashup Score: 0
Micro-AbstractPhase I clinical trials are important in developing novel therapies for patients with metastatic urothelial carcinoma (mUC), and prognostic scores may improve patient selection for enrollment in these studies. We evaluated urothelial carcinoma specific (Bellmunt, Bajorin) and phase I specific (Royal Marsden Hospital (RMH), MD Anderson Cancer Center (MDACC)) prognostic scores in a…
Source: Clinical Genitourinary CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials @OAlhalabiMD @PavlosMsaouel https://t.co/X5eQdB5BRx
-
-
Mashup Score: 0
Micro-AbstractWe performed a propensity score analysis on the role of metastasectomy for patients with metastatic renal cell carcinoma. Our results support the concept that metastasectomy is associated with improved overall survival in this population. This benefit appears to be confined to metastasectomies that achieve complete resection of all known lesions.
Source: Clinical Genitourinary CancerCategories: Latest Headlines, Oncologists2Tweet-
Benefit of Metastasectomy in Renal Cell Carcinoma: A Propensity Score Analysis https://t.co/5TijKDGRvu
-
-
Mashup Score: 1
: A novel prognostic model was recommended for patients with metastatic RCC (mRCC) by the International mRCC Database Consortium (IMDC). In this study, we aimed to externally validate a novel risk model for the IMDC-favorable risk group in patients with mRCC.
Source: Clinical Genitourinary CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
"Very favorable" risk group of mRCC was presented @ASCOGU21 by @dr_aschmidt We externally validated the novel IMDC risk model in "Turkish Oncology Group Kidney Cancer Consortium" database @DrYukselUrun @DrChoueiri @DrDanielHeng @OncoAlert 👇 https://t.co/hYTAdDJARE
-
-
Mashup Score: 1Evolving trends in the management of low-risk prostate cancer - 3 year(s) ago
: To evaluate factors associated with deferred treatment in patients with low-risk prostate cancer and shifts in these factors after recent incorporation of active surveillance into national guidelines.
Source: Clinical Genitourinary CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Nice work M Tzeng, @SBasourakos @MeenaDavuluri @GinaDeMeo3 @HimanshuNagarMD @eemilycheng @WCMUrology @WeillCornell : Evolving trends in the management of low-risk prostate cancer https://t.co/VkYN0XNZgi
-
Hot off the press! NENs of the urinary system. Multi-center retrospective study. Great work led by Bryan Le at UCSF. It took a village to get this done... @PatrickMcGarrah @DianeReidyLagun @BergslandEmily @JaydiDelRivero @apolo_andrea @DrDavidLChan https://t.co/p08Jm9h1G5